• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology
  • About Us
    • Chair's Welcome
    • Contact Us
    • Giving
    • Job Listings
    • News
    • Webinars
  • Clinical Programs
    • Chronic Pelvic Pain Program
    • Family Planning
    • Fertility and Reproductive Health Center
    • Fibroid Treatment Program
    • Gynecologic Oncology
    • Gynecology
    • Labor and Delivery
    • Maternal Fetal Medicine
    • Nurse Midwives
    • Minimally Invasive & Robotic Surgery
    • Obstetrics
    • Women's Pelvic Health
  • Conditions Treated
    • Cervical Cancer
    • Cervical Insufficiency
    • Congenital Abnormalities
    • Endometriosis
    • Fibroids
    • Hirsutism
    • Infertility
    • Menopause
    • Ovarian Fallopian Tube and Primary Peritoneal Cancer
    • Polycystic Ovary Syndrome (PCOS)
    • Pregnancy
    • Premenstrual Syndrome (PMS)
    • Recurrent Pregnancy Loss
    • Reproductive Surgery
    • Sexually-transmitted Diseases
    • Urinary Incontinence
    • Urinary Tract Infection
    • Uterine / Endometrial Cancer
    • Vaginal Yeast Infection
    • Vulvar and Vaginal Cancer
    • Vulvodynia
  • For Patients
    • Coronavirus
    • Patient Stories
    • myUCLAhealth
    • Appointments
    • Clinical Updates
    • FAQs
    • Find a Doctor
    • First Visit
    • Health Plans
    • Locations
    • Medical Records
    • Patient Videos
    • Physicians Update
    • Pregnancy
    • Prescription Refill
    • Resources
    • Vital Signs Newsletters
    • Webinars
  • Clinical Trials
  • Research
    • Yalda Afshar MD PhD Lab
    • Sandra Orsulic PhD Lab
    • Women's Reproductive Health Research Program
  • Education
    • Residency
    • Fellowship Programs
    • Housestaff Roster 2020-21
    • Calendar of Events
    • Grand Rounds and Conferences
    • Medical Students
    • Aerial Tour: Why Choose UCLA?
    • Contact Academic Office
  • Our Expert Team
    • Appointment Request
    • Chronic Pelvic Pain
    • Family Planning
    • Fertility & Reproductive Health
    • Fibroid Treatment
    • Gynecologic Oncology
    • Gynecology
    • Minimally Invasive & Robotic Surgery
    • Nurse Midwives
    • Obstetrics
    • Maternal Fetal Medicine
    • Women's Pelvic Health
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Obstetrics and Gynecology

Research

Research

Research

  • Yalda Afshar MD PhD Lab
    • Meet Our Team
    • Publications
  • Sandra Orsulic PhD Lab
    • Research Areas
    • Lab Reagents for Collaborations
    • Publications
    • Meet Our Team
  • Women's Reproductive Health Research Program
    • Polycystic Ovary Syndrome (PCOS)
    • Awards and Recognition
    • Contact Us
    • Donate Now
    • Meet Our Students
    • Newsletters
    • PCOS Patient Story
    • Photo Gallery & Events
      • Symposium Gallery - Advances In Treating Women’s Infertility & Metabolic Disease
    • Publications & Presentations
    • Student Testimonials
    • UCLA SPARK Campaign
    • Video Gallery
  • Yalda Afshar MD PhD Lab
  • Sandra Orsulic PhD Lab
  • Women's Reproductive Health Research Program
  • Meet Our Team
  • Publications
  1. Home
  2. Research
  3. Yalda Afshar MD PhD Lab

Yalda Afshar MD PhD Lab

Share this

Research Lab of Yalda Afshar, MD, PhD

If you are participating in the PRIORITY Biospecimen study, please contact Christine Jang at cjang@mednet.ucla.edu.

PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a nationwide study of pregnant or recently pregnant people who are either under investigation for Coronavirus infection (COVID-19) or have been confirmed to have COVID-19. This study is being done to help patients and healthcare providers better understand how COVID-19 impacts pregnant people and their newborns. 

 

Profile Photo

Assistant Professor In-Residence
UCLA Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine 

Contact
Email: yafshar@mednet.ucla.edu
Twitter: @yafshar (link to: https://twitter.com/yafshar)

Research Goals

Prenatal Vascular PhenotypeLarger image>

1) Prenatal Vascular Phenotype in Congenital Heart Disease 

Congenital heart defects (CHDs) are the most common cause of congenital anomaly, occurring in ~1% of newborns. Among CHD types, single ventricle (SV) phenotypes have the worst clinical prognoses. These neonates generally survive in-utero; however, there is lifetime morbidity related to vascular sequalae -- protein losing enteropathy, hepatic fibrosis, and pulmonary arterio-venous malformations.  Furthermore, there is a high incidence of mortality in infancy without cardiac transplantation or a series of staged surgical procedures. Despite making up only 5-8% of all CHD cases, SVs account for 25% of infant CHD deaths and only 50-70% survive beyond 5 years. The etiology(ies) remain elusive making intervention purely mechanical. Upstream and/or downstream signaling alterations in endothelial mechano-transduction throughout their life due to the abnormal flow patterns, remains a unifying phenotype. We have termed this the prenatal vascular phenotype.

To understand and target the mechanisms underlying the vascular phenotype, we aim to integrate data through the life course -- the prenatal and postnatal sequalae. We couple prenatal maternal-fetal imaging, underlying genetic predispositions, and developmental endothelial flow dynamics. By linking molecular data and environmental clues, mechanisms underlying SV pathology, and more specifically the prenatal vascular phenotype, will be uncovered. Ultimately, this may improve treatment that arise from loss of vascular integrity. 

Imaging

Imaging

2) Endothelial Cells: Conduits of Translational Medicine

During pregnancy, the umbilical vessels provide a closed maternal-fetal circulatory system via the placenta to the fetus. A monolayer of endothelial cells (ECs) line the lumen of each vessel and translate the forces created by blood flow (35-250 milliliters per minute) into morphological and molecular responses that maintain homeostasis in each vessel of the maternal-fetal unit. Here, freshly isolated umbilical vein ECs, demarcated at the cell-junction by VE-Cadherin (red) and the actin cytoskeleton (green), show a response to fluid flow in vitro similar to that seen in vivo -- the cells elongate along the axis of flow, express Kruppel-Like Factor 2 (blue), and NOTCH1 (pink) polarizes downstream in the cells. Thus, each umbilical cord provides a model to identify the biomarkers responsible for the underlying etiologies of pregnancy-related maternal and fetal disease (i.e. preeclampsia, growth restriction, etc.) and is essential for developing precise mechanistic studies and effective therapeutics in pregnancy.

3) The Umbilical Cord as a Model System

We have identified a population of patients with a clear unmet clinical need because of an underlying chronic dysfunction of hemodynamics related to endothelial cell dysfunction. Despite being born with a morbid CHD, we have a chance to understand downstream complications and interventions that can improve quality of life in these patients with lifelong sequelae related to an abnormal endothelial cell and vascular phenotype.  Amongst non-genetic factors, alterations in hemodynamic forces alone have been shown to cause CHD in other species. A systematic mapping of hemodynamic forces in human CHD is yet to be performed and the potential role of altered flow as a predisposing factor in CHD has yet to be examined. More so, the downstream consequences of the vascular sequalae of CHD involve the same insult of endothelial cells (ECs) -- protein losing enteropathy, hepatic fibrosis, and pulmonary arterio-venous malformations.  We focus on altered flow acting as a modifier in development and contributing to CHD. Flow is a well-defined mechanism and provides a platform to study physical forces that alter hemodynamics and of critical importance of gene expression in prenatally-diagnosed CHD with postnatal sequelae related to the vascular phenotype.

Lab equipmentLarger image >

4) PRIORITY (Pregnancy CoRonavirus Outcomes RegIsTrY)

PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY), a nationwide registry of pregnant and postpartum women with or known or suspected COVID-19. Our team at UCLA has partnered with UCSF to establish this collaboration  to answer critical questions for peripartum, neonatal, and postpartum patients with COVID-19 nationally and globally. Little is known about COVID-19 and its longstanding impact for women and babies. A robust research platform is needed to better understand the pathways of COVID-19 to identify risk factors and develop effective treatments. Our work includes maternal and neonatal outcomes and a biospecimen core to answer clinically relevant questions. 
For more information about the study > 
Donation page > 

Publications

PubMed >
Google Scholar > 
Division of Maternal Fetal Medicine Research and Publications > 
Additional Publications >

Our Lab Team

Helia Imany-Shakibai
Christine Jang, PharmD
Anhyo Jeong
Guadalupe Martinez
Jenny Mei, MD
Allison Woods
Ophelia Yin, MD

Meet our team >

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest